ACE-031 Research Guide

Overview

ACE-031 is the research designation for a recombinant fusion protein consisting of the extracellular ligand-binding domain of human Activin Receptor Type IIB (ActRIIB) joined to the Fc fragment of human immunoglobulin G1 (IgG1). Unlike the short synthetic peptides most commonly studied in laboratory settings, ACE-031 is a considerably larger biologic, with published estimates of its dimeric molecular weight ranging from roughly 70 to 110 kDa depending on glycosylation and assay conditions. It was originally developed by Acceleron Pharma (later in partnership with Shire) as a soluble “decoy receptor” tool for probing activin/myostatin signaling in skeletal muscle research.

Functionally, ACE-031 belongs to the broader class of research reagents known as ligand traps: proteins engineered to bind circulating signaling molecules before those molecules can engage their native cell-surface receptors. In the case of ACE-031, the ActRIIB extracellular domain retains high-affinity binding for myostatin (GDF-8) and several related members of the TGF-β superfamily, including activin A, activin B, GDF-11, and — with lower affinity — BMP-9 and BMP-10. This binding profile has made ACE-031 a widely referenced tool compound in published research on the molecular regulation of skeletal muscle mass. Available for research at Iron Peak Peptides: ACE-031.

ACE-031 was studied in early-phase human clinical research for Duchenne muscular dystrophy (DMD) sponsored by Acceleron Pharma and Shire; those trials were halted in 2011 due to vascular safety observations (epistaxis and telangiectasias) and the clinical development program was subsequently discontinued in 2013. This guide summarizes the peer-reviewed and preclinical literature describing ACE-031 as a laboratory tool for studying activin receptor signaling and is not a protocol, dosing, or clinical-use resource; it does not describe or endorse any therapeutic application in humans.

Molecular Profile & Structure

ACE-031 is structurally distinct from short synthetic peptides in that it is a dimeric fusion protein rather than a linear amino acid chain of a few residues. Each monomer combines the extracellular domain of ActRIIB — the portion of the native receptor responsible for ligand recognition — with the Fc region of human IgG1, which mediates dimerization through disulfide bonding and confers an extended circulating half-life relative to the native receptor ectodomain alone. Published pharmacokinetic research places the terminal half-life of ACE-031 in the range of several days in both animal models and human volunteers, consistent with Fc-fusion protein pharmacology generally.

Because ACE-031 is a biologic produced recombinantly (historically in Chinese hamster ovary, or CHO, cell expression systems), it does not have a single fixed small-molecule CAS registry identifier or a defined molecular formula in the way short synthetic peptides do; its physicochemical characterization is instead expressed in terms of amino acid sequence, glycosylation pattern, and apparent molecular weight by size-exclusion chromatography or SDS-PAGE. Researchers characterizing ACE-031 preparations typically report purity by SDS-PAGE and identity by binding assays (e.g., surface plasmon resonance or ELISA against myostatin and activin A) rather than by classical small-molecule spectroscopic methods.

Mechanism of Action

The proposed mechanism of ACE-031 centers on its function as a soluble decoy for the native, membrane-bound ActRIIB receptor. In physiological skeletal muscle signaling, myostatin and activin A bind ActRIIB on the surface of muscle cells, triggering recruitment of a type I receptor (ALK4/ALK5) and subsequent phosphorylation of SMAD2/3 transcription factors. Activated SMAD2/3 complexes translocate to the nucleus and modulate the transcription of genes that constrain skeletal muscle fiber growth, contributing to the negative regulation of muscle mass that is characteristic of myostatin/activin signaling.

Because ACE-031 presents a soluble, high-affinity ActRIIB extracellular domain in circulation, published research describes it as sequestering myostatin and activin A (along with related ligands such as GDF-11) before these ligands can engage membrane-bound ActRIIB. This ligand-trapping activity is proposed to reduce downstream SMAD2/3 activation in skeletal muscle tissue, thereby disinhibiting hypertrophic signaling pathways. Preclinical research in murine models using RAP-031, a murine ActRIIB-Fc analog structurally comparable to ACE-031, has been used to dissect this mechanism further, describing increases in both slow-twitch (type I) and fast-twitch (type II) muscle fiber cross-sectional area following administration, indicating that the ligand-trapping mechanism affects fiber types broadly rather than selectively.

Because ActRIIB ligands beyond myostatin — including activins and certain bone morphogenetic proteins — participate in signaling outside skeletal muscle (for example in reproductive endocrinology and vascular biology), published safety research has also examined off-target consequences of broad ActRIIB ligand trapping, which is relevant context for interpreting the vascular findings that led to the discontinuation of ACE-031’s human clinical development.

Key Research Findings

Foundational preclinical work by Pistilli and colleagues examined administration of a soluble ActRIIB receptor construct in mouse models and reported increases in skeletal muscle mass driven by hypertrophy of both type I and type II muscle fibers, independent of fiber-type-specific selectivity, providing early mechanistic support for ActRIIB ligand trapping as a driver of generalized muscle growth (Pistilli et al., 2010).

A single ascending-dose study of ACE-031 in healthy, postmenopausal women — designed to characterize pharmacokinetics, pharmacodynamics, and tolerability — reported measurable increases in lean body mass and changes in biomarkers of muscle regulatory signaling following single-dose administration, along with characterization of the compound’s circulating half-life and dose-dependent pharmacodynamic response (Attie et al., 2013).

Campbell and colleagues reported results of a randomized, placebo-controlled clinical trial examining ACE-031 in ambulatory boys with Duchenne muscular dystrophy. The trial, sponsored by Acceleron Pharma and Shire, was stopped after the second dosing regimen due to safety observations including epistaxis and telangiectasias; the published report describes both the observed effects on lean body mass and the safety signals that led to trial discontinuation, and remains a key reference for researchers evaluating the translational safety profile of ActRIIB-targeted ligand traps (Campbell et al., 2017).

More recent preclinical research has extended ACE-031 characterization to non-human primate models. A study administering ACE-031 to common marmosets (Callithrix jacchus) over a 14-week period reported significant increases in body weight and lean body mass relative to vehicle-treated controls, along with functional strength measures, offering a translational bridge between rodent mechanistic studies and the earlier human clinical experience (marmoset ActRIIB study, 2025).

Broader review literature on myostatin inhibition strategies situates ACE-031 alongside other ActRIIB-pathway modulators — including bimagrumab, an anti-ActRII monoclonal antibody, and follistatin-based constructs — as part of a comparative framework for evaluating the mechanistic and translational tradeoffs among different approaches to activin/myostatin pathway inhibition in muscle biology research (myostatin inhibition review literature, 2024).

Research Applications

ACE-031 is used in laboratory research chiefly as a pharmacological tool for investigating activin/myostatin receptor signaling in skeletal muscle biology. Because it acts upstream of the ActRIIB receptor itself, researchers use ACE-031 (or species-matched analogs such as RAP-031 in mice) to interrogate the physiological consequences of broadly inhibiting ActRIIB ligand signaling, including its effects on muscle fiber cross-sectional area, satellite cell activity, and downstream SMAD2/3 transcriptional programs.

Comparative pharmacology research also uses ACE-031 as a reference compound when characterizing newer ActRIIB-pathway modulators, including monoclonal antibodies and small-molecule or peptide-based approaches, allowing researchers to benchmark selectivity, pharmacokinetics, and magnitude of muscle-mass effects against a well-documented decoy-receptor mechanism. Additional research applications include translational pharmacology and toxicology studies examining off-target consequences of ActRIIB ligand trapping — such as vascular and endocrine findings reported in earlier human trials — which remain an active area of investigation for researchers designing next-generation, more selective myostatin pathway inhibitors.

Non-human primate and rodent models employing ACE-031 or its analogs continue to serve as reference points for muscle wasting research broadly, including research contexts such as sarcopenia, cachexia, and neuromuscular disease models, always within a strictly preclinical, laboratory research framework.

References

1. Pistilli EE, et al. (2010). Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. Journal of Applied Physiology.
2. Attie KM, et al. (2013). A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle & Nerve.
3. Campbell C, et al. (2017). Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. Muscle & Nerve.
4. ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus). (2025).
5. Therapeutic applications and challenges in myostatin inhibition for enhanced skeletal muscle mass and functions. (2024). Molecular and Cellular Biochemistry.